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ABSTRACT 
 
Rationale. The pathogenesis of PAH remains unclear. The four microRNAs representing the miR-143 
and miR-145 stem loops are genomically clustered.  
 
Objective. To elucidate the transcriptional regulation of the miR-143/145 cluster, and the role of miR-
143 in PAH. 
 
Methods and Results. We identified the promoter region that regulates miR-143/145 miRNA 
expression in pulmonary artery smooth muscle cells (PASMCs). Using a reporter vector, we 
characterized and mapped PAH-related signaling pathways, including estrogens receptor (ER), liver X 
factor/retinoic X receptor (LXR/RXR), TGF-β (Smads), and hypoxia (HRE) that regulated levels of all 
pri-miR stem loop transcription and resulting miRNA expression. We observed that miR-143-3p is 
selectively upregulated compared to miR-143-5p during PASMC migration. Modulation of miR-143 in 
PASMCs significantly altered cell migration and apoptosis. In addition, we found high abundance of 
miR-143-3p in PASMCs-derived exosomes. Using assays with pulmonary arterial endothelial cells 
(PAECs) we demonstrated a paracrine pro-migratory and pro-angiogenic effect of miR-143-3p enriched 
exosomes from PASMC. Quantitative PCR and in situ hybridisation showed elevated expression of 
miR-143 in calf models of PAH as well as in samples from PAH patients. Moreover, a protective role 
for miR-143 in experimental PH in vivo was demonstrated in miR-143-/- and antimiR143-3p-treated 
mice exposed to chronic hypoxia in both preventative and reversal settings. 
 
Conclusions. MiR-143-3p modulated both cellular and exosome-mediated responses in pulmonary 
vascular cells, whilst inhibition of miR-143-3p blocked experimental PH. Taken together these findings 
confirm an important role for the miR-143/145 cluster in PAH pathobiology. 
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Non-standard Abbreviations and Acronyms. 
 
9cRA: 9-cis-Retinoic acid 
22R: 22R-Hydroxycholesterol 
BMP: Bone morphogenetic protein 
ER: Estrogen receptor 
HPAH: heritable PAH 
HRE: Hypoxia response element 
IPAH: idiopathic PAH 
LXR/RXR: Liver X Receptor/Retinoic X Receptor 
miRNAs: Non-coding microRNAs 
PAECs: Pulmonary artery endothelial cells 
PAH: Pulmonary arterial hypertension 
PASMCs: Pulmonary artery smooth muscle cells 
PCNA: Proliferating Cell Nuclear Antigen  
PDGF: Platelet-Derived Growth Factor 
PH: Pulmonary hypertension 
qPCR: Quantitative PCR 
RV: Right ventricle 
RVH: Right ventricular hypertrophy 
RVP: Right ventricular pressure 
SAP: Systemic arterial pressure 
TGF-β: Transforming growth factor-β 
TF: Transcription factors 
TSS: Transcription start site 
VEGF: Vascular Endothelial Growth Factor 
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INTRODUCTION 
 
 Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease with an 
estimated prevalence of ~15 cases per million1. The pathogenesis of PAH includes sustained 
vasoconstriction and abnormal progressive fixed vascular remodelling. This is accompanied by 
endothelial dysfunction and activation of fibroblasts and smooth muscle cells2. PAH may be initiated 
by loss of endothelial integrity and dysfunction resulting in exposure of underlying cells to circulating 
factors, leading to proliferation and apoptosis resistance in the adventitia, smooth muscle media and the 
formation of a neointima3. Clinically, PAH is subdivided into several groups, including: idiopathic 
(IPAH), heritable (HPAH) and PAH associated with other diseases (APAH). Female gender is 
considered a risk factor per se for all PAH subtypes, since it is more frequent in women than men4. 
 
 Most cases of HPAH (>70%), and some IPAH cases (approximately 20%), are caused by 
mutations in the bone morphogenetic protein type II receptor gene (BMPR2) that impairs BMP signaling 
pathway via Smad1, Smad5 and Smad8, and leads to an increased activity of TGF-β pathway via non-
canonical and canonical Smad2/3 signalling5. However, since PAH is incompletely penetrant, BMPR2 
mutations alone may not be sufficient to cause disease, so that a ‘second hit’ including other genetic 
and/or environmental factors may be required for the clinical manifestation of  PAH6. Triggers for 
disease may include inflammation, hypoxia and shear stress or vascular injury. 
 
 MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression 
by recognizing the 3’-untranslated regions (3’-UTR) of target coding mRNAs and abolishing their 
expression by blocking translation or accelerating their degradation7. Coding sequences of miRNA are 
distributed across the entire genome and can be classified by their location in either intragenic, typically 
within an intron sequence (mirtrons), or intergenic regions. An independent promoter region drives 
expression of intergenic miRNAs. Thus, most intergenic miRNAs are transcribed by RNA polymerase 
II and the basal transcriptional machinery8. Although little is known about the transcriptional regulation 
of miRNA expression, this process has been proposed to be orchestrated by the cellular pool of 
transcription factors that interact with the promoter region similarly to protein coding genes. Recent 
studies have developed bioinformatics algorithms to predict the miRNA core promoters, focused on the 
upstream sequence of the precursor (pri-miRNA)9. In the particular case of intergenic miRNA, the 
promoter region is predicted to be ~20 kb upstream of the pri-miRNA and exhibits similar conservation 
patterns to the promoters of protein coding genes. Nonetheless, only a few papers have reported 
experimental evidence that validate those regions as core promoters. 
 
 In blood vessels, one of the most studied miRNA expressed by vascular smooth muscle cells 
(VSMC) is the miR-143/145 cluster, which has a pivotal role in VSMC differentiation and disease10-12. 
MiR-145 expression has been reported to control VSMC phenotype, restoring the contractile phenotype 
in atherosclerotic plaques13 and coronary collateral growth in the metabolic syndrome14, among others. 
Expression of the miR-143/145 cluster is decreased in conditions associated with acute and chronic 
vascular stress, such as aortic aneurysms12 and coronary artery disease15. MiR-145-5p is able to control 
vascular neointimal lesion formation16. Up-regulation of miR-145-5p was observed in pulmonary artery 
VSMCs and in lung tissue from patients with idiopathic and heritable pulmonary arterial hypertension 
(PAH)17. However, the transcriptional regulation of the cluster has not been defined with respect to 
mediators of PAH nor has the role of miR-143 been addressed in PAH. Interestingly, despite their 
predominantly intracellular localization, miRNAs have been recently found in extracellular 
compartments, such as exosomes18. These exosomes represent a specific subtype of secreted 
membrance vesicles of 30-130 nm formed through the fusion of multivesicular endosomes with the 
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plasma membrane19. Exosomes convey a wide array of molecules such as proteins and nucleic acids, 
including mRNAs and miRNAs, and have emerged as regulators of cell-cell communication and 
paracrine signaling mediators during physiological and pathological processes in various diseases20, 21. 
Here, we studied the transcriptional regulation of the miR-143/145 cluster and its contribution to the 
development of PAH. 
 
 
METHODS 
 
 Cell culture methods and reagents17; cloning the miR-143/145 proximal promoter and reporter 
vectors analysis RNA extraction, reverse transcription and TaqMan qPCR Analysis17 and in situ 
hybridisation; Smad3 decoy assays; Isolation of exosomes from cell media; Cell migration22 and 
proliferation23 assays; Western blot and immunohistochemistry analyses24; Animal housing and 
experimentation including chronic hypoxia exposure and hemodynamic measurements24; and Statistical 
analysis, were carried out as previously reported elsewhere and are described in the expanded Methods 
section in the online data supplement, available online at http://circres.ahajournals.org. 
 
 
RESULTS 
 
Identification and cloning of the MIR143HG promoter 
 
 We first sought to define the transcriptional regulation of the miR-143/145 cluster. According 
to miRStart data and using the human genome assembly GRCh38, the transcription start site (TSS, 
position +1) is likely to be located at position 149406877 in the plus strand of chromosome 5, 22,041 
bp upstream of the pri-miR143 precursor. Supporting this TSS, we identified a local TATA-box at 
position (-26) (TATAAG), as well as 2 likely CAAT-boxes (CCAAT) at positions (-94) and (-54), and 
an E-box at position (-113) (CACGTG) (Figure 1A). 
 
 We selected a GC-rich (58.5%) region of 1.5 kb spanning from position (-1354) to (+202), since 
the alignment with the homologous region from other mammalian species was strong (match >60%). A 
proximal region of 0.5 kb was also selected from (-304) to (+202) for mapping transcriptional activity.  
Despite some GC-rich regions in the promoter, no putative CpG islands were predicted and 
experimentally the DNA demethylating reagent 5-Aza-2’-deoxycytidine did not affect the pri-miR-
143/145 expression either in PASMC or PAEC/HUVEC (Supplementary Figure S1). 
 
Analysis of TF binding sites 
 
 The in silico analysis of the 1.5kb sequence of miR-143/145 promoter revealed a number of 
putative binding sites for transcriptional factors (TFs). We treated PASMC with their respective ligands, 
and pri-miR precursors and mature forms were detected by qPCR and luciferase reporter assays. Based 
on 3 predicted estrogen receptor binding sites at position (-1129), (-801) and (-14), we treated PASMC 
with estradiol (E2). E2 induced the expression of both pri-miR-143 and pri-miR-145 after 24 h (Figure 
1B). The respective mature lead strand miRNAs were upregulated correspondingly (Figure 1C). 
Reporter vectors confirmed the increased transcriptional activation of the miR-143/145 promoter in 
response to E2 (Figure 1D). Using site-directed mutagenesis, we studied which of the 3 ER sites are 
necessary for ER-dependent induction of miR-143. We identified that the sites at positions (-801) and 
(-14) are required since the activity of the promoter is not enhanced when these sites are mutated.(Figure 
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1E). We also identified several putative binding sites for the retinoic acid receptor, which is well known 
to act in combination with the liver X receptor (LXR/RXR)25. PASMC treated with 9-cis-retinoic acid 
(9cRA) and/or 22R-hydroxycholesterol (22R) upregulated both precursor and mature forms of the 
cluster (Figure 1F and 1G).  The transcriptional activity of the reporter vectors showed a small but 
significant induction for the minimal promoter (p0.5-luc) but this was more marked for the full-length 
sequence (p1.5-luc) (Figure 1H). Activity was dependent on the binding sites located at (-673), (-4) and 
(+98) (Figure 1I). We also identified 2 putative hypoxia response elements (HRE) and, upon 
stimulation, we observed a 2-fold induction in pri-miR-143 expression and moderate induction for pri-
miR-145 in PASMC cultured in hypoxic conditions (Figure 1J). Expression of mature miR-143-5p and 
-3p were upregulated in the same pattern but only miR-145-5p and not miR-145-3p was induced (Figure 
1K). Moreover, both minimal and full-length reporters responded to hypoxia (Figure 1L). Mutation 
analysis confirmed that the HRE site in (-113) which overlaps the basal transcription element E-box, 
was critical since the minimal promoter p0.5-luc maintains the response to hypoxia (Figure 1M). We 
also searched for STAT sites in the MIR143HG promoter. It was predicted in silico that several 
consensus sites for STAT5A, STAT5B, STAT1 and STAT3 were in the region between (-1354) and (-
304). None were located in the minimal 0.5kb region.  
 
The miR-143/145 promoter responds to TGF-β 
 
 Several putative binding sites for Smad proteins for both TGF-β and BMPs signaling pathways 
were localised (Figure 1A). TGF-β1 increased the expression of precursor and the 4 mature forms of 
the miR-143/145 cluster (Figures 2A and 2B) in PASMC. Moreover, treatment of cells with a specific 
inhibitor of the TGF-β receptor ALK5, SB525334, completely abolished this induction (Supplementary 
Figure S2). In contrast, BMP4 treatment did not affect the basal levels of the precursor forms or the 
mature miRNAs (Figure 2A and 2B). We therefore focused on 2 putative Smad3 binding sites. Because 
TGF-β1 induced the transcriptional activity of the full length reporter but not the minimal p0.5-luc 
construction (Figure 2C), we assayed the Smad3 element at position (-592). Site-directed mutagenesis 
of this Smad3 binding site abolished the activity of the reporter in response to TGF-β1 (Figure 2D). 
Next, using release 138 of the 1000 Genomes Project26 on Ensembl we found 3 single nucleotide 
polymorphisms (SNPs) affecting the Smad3 binding site at position (-592). One of these was outside 
the consensus motif (rs145177914, [C>T]). However, the remaining two disrupted the Smad3 binding 
site (rs12517403, [T>C]; and rs116423755, [G>A]). To test the functionality of this, a Smad3 decoy 
assay was designed using FAM-labelled PTO-ODN bearing the SNPs. The wild type and a scramble 
sequence were used as controls. A dose-response assay co-transfecting WT and mock probes in 
PASMC, with or without TGF-β1 treatment, demonstrated that increasing WT probe reduces the 
expression of pri-miR-143 and pri-miR-145, as well as Col1A1 as a TGF-β1 positive control, validating 
this sequence as a Smad3 binding site (Supplementary Figure S3). Furthermore, PTO-ODN probes 
bearing Smad3 SNPs were unable to block the TGF-β1 stimulus, confirming the functionality of that 
Smad3 site (Figure 2E and 2F). 
 
Manipulation of miR-143/145 cluster affects PASMCs migration  
 We sought to assess the impact of promoter activation on PASMC migration, proliferation and 
apoptosis. We first sought to assess the effect of wound assay on induction of the miR-143/145 axis in 
response to this stress and during the healing response. Using wounding assays, we showed rapid 
transcriptional activation of the pri-miR-143/145 precursors at 3 h, which was maintained over time for 
pri-miR-143 but later repressed for pri-miR-145 (Figure 3A). Pri-miR-143 up-regulation was 
accompanied by a corresponding increase in mature miR-143-3p. By contrast, miR-145-5p expression 
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did not change during cell migration (Figures 3B). In addition, the expression of their respective 
passenger strands, miR-143-5p and miR-145-3p, did not change significantly during the wound closure 
(Figure 3C). These responses were also observed but even enhanced in distal PASMC from PAH 
patients (Supplementary Figure S4). Moreover, overexpression of miR-143-3p using pre-miRNA 
significantly induced PASMCs migration, while antimiR-mediated knockdown of miR-143-3p 
decreased the migration rate (Figure 3D-G). In contrast, stimuli reduced cell migration and altered the 
expression pattern of pri-miR-143 and pri-miR-145 (Supplementary Figure S5). Q-PCR confirmed the 
overexpression and knockdown of miR-143 (Figure 3F and G). In contrast, using the BrdU 
incorporation assay and PCNA protein analysis, PASMC proliferation did not change in cells treated 
with pre-miR143 compared to the control groups whereas apoptosis was induced with antimiR-143 
(Supplementary Figure S6A-C). We also assessed the influence of DNA damage to miR-143 expression 
in PASMC.  We treated PASMC with TNF-α (100 ng/mL), IL-6 (100 μM) or PDGF (30 ng/mL) for 48 
h to induce DNA damage. γH2AX nuclear staining confirmed  DNA damage in PASMC and miR-143 
expression was upregulated (See Supplementary Figure 6D, E). Further, we assessed the miR-143/145 
promoter activity during cell migration. We analysed GFP reporter vectors from the promoter sequence 
by nucleofection in PASMC. Both minimal (0.5kb) and full-length (1.5kb) promoter constructions 
showed GFP induction in migrating cells leading from the scratch wound border (Figure 3H-J). We 
next performed a gene expression microarray experiment on PASMCs transfected with the miR-143 
mimic and identified 68 regulated targets that are involved in cell migration (Table S1).  Further, 
“migration of cancer cells” was identified as a significantly enriched pathway (p=0.0001) identified by 
ingenuity pathway analysis (Table S2 and Supplementary Figure S7). These findings are consistent with 
the hypothesis that miR-143 can increase migration in PASMCs. We did not observe an effect of miR-
143 knockout on FAK in total lung homogenates (Supplementary Figure S8A,B). Potentially, Stat3 
could have a role in the transcriptional regulation of miR-143. However, we observed no increase in 
STAT 3 (phospho Y705) by western blotting in migrating PASMCs, although miR-143 was upregulated 
5 fold in these cells (Supplementary Figures S8C,D).  
 
 
miR-143-3p induced in PASMCs can be transferred to PAECs and induces endothelial cell 
migration 
 
 Having observed increased levels of miR-143-3p in PASMC exposed to PAH stimuli, we 
explored whether miR-143-3p was involved in cell-cell communication between PASMCs and PAECs. 
We performed a co-culture assay of PAEC with PASMC in Boyden chambers, in which cells were 
physically separated by a membrane to prevent direct cell-cell contact (Figure 4A). In order to visualize 
whether miRNAs released from PASMCs in extracellular vesicles are transported to PAECs, we 
transfected PASMC with a Cy3-labeled precursor miRNA prior to co-culturing with PAECs for 24 h. 
Fluorescence imaging of PAECs showed that Cy3-labeled miRNAs derived from PASMCs could be 
detected in PAECs in the co-culture system (Figure 4B). Moreover, the basal level of miR-143-3p in 
PAECs was upregulated by co-culture with PASMC showing transfer of endogenous miR-143 (Figure 
4C). Levels of miR-143 were upregulated after co-culture with miR-143-transfected PASMCs for 24 h 
and 48 h (Figure 4D). or PAECs co-cultured with miR-143-3p transfected PASMCs (Figure 4E, G) or 
exposed to conditioned medium from transfected PASMCs  showed increased migration compared to 
controls (Figure 4G, H). Q-PCR confirmed the increase in miR-143-3p in recipient PAECs.  
Extracellular miR-143-3p transport is mediated by exosomes  
 
 Previous studies have reported that exosomes can carry functional miRNAs between cells18, 27. 
To investigate the function of the extracellular vesicles containing miR-143-3p in the co-culture system 
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and condition medium, we isolated exosomes from the medium of PASMCs transfected with different 
concentrations of pre-miR143-3p and quantified the levels of miR-143-3p in the exosomes and 
transfected cells. MiR-143-3p expression was clearly detected by qPCR in PASMC-derived exosomes 
from culture supernatant, which displayed the expected diameter and size and markers (Figure 5A-C). 
The incorporation of miR-143-3p into exosomes was confirmed by qPCR assessing both the cell-
associated and extracellular levels of miR-143-3p 24 h post-transfection. As expected, we found a dose-
dependent increase in miR-143-3p in PASMCs (Figure 5D) and accumulation of miR-143-3p in 
exosomes derived from PASMCs (Figure 5E). In addition, we performed a wound-healing assay to 
examine whether exosome-derived miR-143-3p has similar functional effects on PAECs to that 
observed in the co-culture and conditioned medium experiments. PASMC-derived exosomes induced 
PAEC migration in a similar manner to that observed in co-culture and conditioned medium 
experiments (Figure 5F), with a corresponding increase in the intracellular levels of miR-143 (Figure 
5G). This resembled the effect of direct transfection of the miR-143 precursor into PAECs (Figure 5H 
and 5I). Further, exosome-derived miR-143 or direct transfection of pre-miR-143 induced angiogenesis 
in matrigel assays in PAEC (Figure 5J-L). Direct transfection with pre-miR-143-3p in PAECs had no 
effect on cell proliferation analyzed by PCNA western blot and BrdU incorporation or apoptosis 
(Supplementary Figure S9A-D). Using a Cy3-labelled pre-miR-143 transfected into PASMC and 
purification of resulting PASMC-derived exosomes, we demonstrated uptake into PAEC by 
fluorescence microscopy (Supplementary Figure S9E). Finally, we demonstrated that the induction of 
migration by miR-143-enriched PASMC-derived exosomes in PAEC was inhibited by transfection of 
the PAEC by antimiR-143 (Supplementary Figure S9F, G). We also carried out an expression 
microarray on PAECs treated with exosomes from PASMCs transfected with scramble or pre-miR-143. 
We observed the regulation of multiple targets involved in cell death and survival (Table S3 and S4). 
Further these targets might suggest that miR-143 reduces cell death in PAEC (Supplementary Figure 
S10).  
 
 
MiR-143-3p is upregulated in PAH in vivo in animals and in humans 
 
 The involvement of miR-143-3p in PAH has not been investigated. Based on the above data, 
we sought to address this using experimental models and human samples. We found a consistent up-
regulation of miR-143-3p expression in whole mouse lung (Figure 6A) and right ventricle (Figure 6B) 
in response to hypoxia. Further, in primary PASMC from PAH patients, both miR-143-3p and -5p 
expression levels were also significantly upregulated compared to control PASMC from healthy 
volunteers (Figure 6C). In situ staining also highlighted the expression of miR-143-3p in the RV of 
mouse hearts showing elevation after hypoxia (Supplementary Figure S11A). Further, qPCR studies 
showed the presence of miR-143-5p and -3p in both cardiomyocyte and fibroblast cells derived from 
normal mouse hearts (Supplementary Figure S11B). Furthermore, in situ staining also revealed 
increased miR-143 in the vascular wall of the small pulmonary arterioles of hypoxic neonatal calves 
and cattle with Brisket disease, a naturally occurring large animal model of hypoxic pulmonary 
hypertension (Figure 6D and Supplementary Figure S12A). Early and sustained activation of miR-143 
was observed in the rat sugen/hypoxia model (Supplemenatary Figure S12B). Correlating with these 
findings in PAH animal models, miR-143-3p expression was also increased in the smooth muscle layer 
of constrictive and complex arterial lesions of PAH patients compared with healthy controls (Figure 
6E).   
 
Direct knockout of miR-143 stem loop and pharmacological inhibition of miR-143-3p in mice 
alleviates the development of PH in vivo 
9 
 
 
 Finally, we evaluated the effect of genetic ablation of the miR-143 stem loop on the 
development of PH. To test this, we challenged 8-week-old miR-143-/- mice (KO) and age-matched 
control mice with 14-day exposure to chronic hypoxia. Although miR-143 KO had no effect on systemic 
arterial pressure (SAP) (Figure 7A), there was a significant reduction in right ventricular systolic 
pressure (RVSP) and right ventricular hypertrophy (RVH) in miR-143 KO mice compared to wild-type 
controls (Figure 7B and 7C). MiR-143 has been shown to decrease Akt-Ser473 phosphorylation28. We 
did not observe a difference in AktSer473 phosphorylation in RV extracts from controls vs miR-143-/- 
mice (Supplementary Figure S13). Histopathologically, and consistent with the hemodynamic data, 
miR-143 KO mice exhibited a significant reduction in pulmonary vascular remodelling when compared 
with wild-type mice (Figure 7D).No effect was observed on microvascular density in the RV from KO 
mice vs controls (Supplementary Figure S14). The induction of migration and tube formation 
observed by exosomal miR-143 transfer might be beneficial in the context of microvessel 
perfusion. We assessed microvessel density in the lungs of hypoxic WT and miR-143-/- 
animals. We observed a significant reduction in the number of vessels in the lungs of miR-143-
/- vs WT mouse lungs (Supplementary Figure 14E). To test whether knock-down of miR-143-3p 
could reverse experimental PH in vivo, synthetic anti-miRNA specific for miR-143-3p was 
subcutaneously delivered to mice exposed to chronic hypoxia on days 1 and 8 of the 14-day hypoxic 
exposure (Figure 7E). To verify down-regulation of miR-143, we measured miR-143-3p in treated mice 
by qPCR of RNA from whole lung homogenates or isolated pulmonary arteries (Supplementary Figure 
S15A-C). In normoxic conditions, RVSP and RVH were unchanged (Figure 7F and 7G). For the treated 
mice exposed to chronic hypoxia, the miR-143-3p anti-miRNA group showed a significant reduction 
in RVSP compared with vehicle- and scramble-treated groups (Figure 7F). By contrast, no changes 
were observed in RVH, systemic arterial pressure and vascular remodelling (Figure 7G and H, Figure 
S16). PCNA analysis demonstrated that miR-143 KO did not affect cell proliferation during hypoxia-
induced PH model in vivo, consistent with in vitro cell proliferation results (Supplementary Figure S15 
D,E). Finally, we performed a reversal study with induction of hypoxia prior to initiation of antimiR-
143 treatment (Figure 7I-L). We show that delayed antimiR-143 treatment reverses RVSP, RVH and 
decreased vascular remodelling compared to controls (Figure S16).  
 
 
DISCUSSION 
 
 In the current study, we identified the promoter region and characterized several PAH-related 
signaling pathways that regulate miR-143/145 expression. Moreover, we demonstrated novel miR-143-
3p/exosome-mediated cell-cell communication between PASMCs and PAECs, contributing to the SMC 
and EC cell migratory phenotypes that are involved in the pathogenesis of PAH. In addition, in vivo 
data revealed genetic deletion and pharmacological inhibition of miR-143 prevented the development 
of hypoxia-induced PH and reversed it when given after the induction of hypoxia.  
 
 Our previous study demonstrated that elevated levels of miR-145-5p in the lung vasculature are 
associated with PAH. This scenario was further corroborated in a PH mouse model and using miR-145 
knock-out mice, which exhibited a protective phenotype during the development of hypoxia-induced 
PH17. Coding sequences for miR-143 and miR-145 are highly conserved, and lie in close proximity to 
each other on murine chromosome 18 and human chromosome 5. However, the promoter region and 
the transcriptional regulation of miR-143/145 expression have hitherto been unknown, except for a 
previous paper reporting a serum response element ~3.3kb upstream from the pri-miR-143 locus29. 
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Bioinformatics tools predicted the TSS for this miRNA cluster to be located about ~22 kb upstream of 
the pri-miR-143 precursor. Here, we have dissected some of the signaling pathways that regulate miR-
143/145 expression at the promoter level. Firstly, the estrogen receptor clearly triggers the expression 
of the cluster, which is in line with the fact that gender per se is a risk factor for the development of 
PAH30. Our studies used female mice and it would be important to study equivalent strategies in males. 
We found 2 ER binding sites which seem to cooperate in effective stimulation. In the same way, up to 
3 different LXR/RXR binding sites appear to cooperate in the response to 9cRA and oxysterols such as 
22R. These oxysterols are oxidized species derived from cholesterol and it has been recently reported 
that their levels are increased in the vasculature of patients with hypoxic conditions31. Indeed, hypoxia 
itself can clearly induce the expression of the cluster. This is in keeping with the fact that approximately 
20% of hypoxia-induced transcripts are for non-coding RNA32, in line with the role of chronic hypoxia 
and reactive oxygen species in the development of pulmonary hypertension 33. In addition, we assessed 
the impact of TGF-β signaling on this novel promoter region. In agreement with previous reports5, 34, 
we demonstrate that TGF-β1, but not BMP4, induces the expression of miR-145 and miR-143. No 
further characterization was carried out previously regarding the Smad binding site(s) involved. 
Although we have identified an important component of the regulation of the miR-143/145 cluster in 
identification of a promoter region, our study provides limited knowledge relating to the regulation of 
the promoter by transcription factors in response to wound healing. Further studies will be required to 
address this limitation. 
 
 Cell proliferation and migration are both necessary for vascular remodeling, and their 
dysregulation in PAEC and PASMC compartments is associated with PAH pathophysiology, as 
numerous in vivo and in vitro studies have previously shown10, 35, 36. Recently, several studies have 
reported that miRNAs associated with vascular remodeling can regulate cell proliferation and migration 
(reviewed by Grant et al., 2013)37. Our previous study on miR-145 demonstrated that miR-145 mimic 
delivery inhibits cell proliferation of PASMCs, but had no effect on cell migration17. In addition, other 
studies have shown that miR-143 and miR-145 are not redundant and hence do not always act in parallel 
in vitro and in vivo10, 29. We found a sustained and significant up-regulation of both pri-miR-143 and 
mature miR-143 from 3 hours to 24 hours in migrating PASMCs, which was not mirrored by changes 
in miR-145. This suggests that there may be differential post-transcriptional regulation of each 
individual miRNA within the cluster. This alternative processing has been already reported for other 
miRNA clusters, for example the up-regulation of all members of the polycistronic miR-17~92 cluster 
during endothelial differentiation of mouse embryonic stem cells apart from miR-92a, which is 
repressed38. Nevertheless, even though the transcriptional up-regulation of pri-miR-143/145 occurs 
early, and the fact that the promoter sequence has putative binding sites for KLF6, a transcription factor 
recently related to vascular cell migration22, we found that this pathway is not involved in PASMC 
migration. Here we demonstrate that miR-143-3p significantly increases during cell migration. We also 
show that miR-143 overexpression induces PASMC migration, whereas miR-143-3p knock-down 
inhibits this effect. This reduction in cell migration is consistent with in vivo data showing that miR-
143 KO mice (and mice treated with antimiR) exhibit protection from PH. By contrast, we did not 
observe any effect of miR-143 on the proliferation of PASMCs in vitro or in vivo, as measured by 
PCNA expression and BrdU analysis. Consequently, the fact that miR-143 has been previously reported 
as a tumor suppressor by inhibiting proliferation and migration in several cancer cells39, 40 suggests that 
its function strongly depends on the specific cellular context. Mechanistically, we used an unbiased 
approach to assess the effect of miR-143 mimic on the transcriptional profile of PAMSCs. Informatic 
analysis of the data highlighted a migratory phenotype. MiR-143 may act via multiple mechanisms in 
PASMCs and indeed PAEC following exosome-mediated transport and uptake, including cell migration 
and apoptosis (PASMC) and cell death/survival and angiogenesis (PAEC). This will require detailed 
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further analysis but suggests a complex environment where miR-143 upregualtion in hypoxia or 
inhibiton (therapeutically) can modulate phenotypes in both PASMC and PAEC compartments. A 
recent study has highlighted the importance of cell:cell transport from SMC to EC and resulting function 
of the miR-143/5 axis on angiogenesis through modulation of genes including hexokinase-241. We did 
not observe equivalent changes in hexokinase-2 (not shown), perhaps reflecting differences in transport 
mechanisms observed and/or receipent cell types (here primary PAEC). Clearly, cell:cell 
communication of miR-143 (and likely miR-145) is of fundaemental importance in related pathological 
settings. As we observed both cardiac and lung phenotypes with miR-143 loss, the generation of 
conditional knockouts will help define cell-specific contributions to the underpinning role of miR-143 
in this setting. 
 
 It was recently reported that exosomes are effective carriers of miRNAs, and the identification 
of exosomal miRNAs has been performed by a number of researchers21. Exosomes are known to be 
mediators of extracellular communication in cardiovascular diseases, including atherosclerosis20, 
cardiac hypertrophy42 and myocardial infarction43. Previous studies demonstrated that exosomes 
derived from endothelial cells convey both miR-143 and miR-145 to smooth muscle cells, affecting 
their vascular functions20. Therefore, it is reasonable to speculate that cell-cell communication in the 
pulmonary vascular system is relevant to the cellular function changes that participate in the 
pathogenesis of PAH. In the current study, we identified a novel exosome-mediated miRNA 
communication between PASMCs and PAECs, contributing to the induction of smooth muscle cell-
stimulated endothelial cell migration. We provide the first evidence that miR-143 acts as a paracrine 
signalling mediator and is involved in the induction of PAEC migration but not proliferation. We found 
that isolated exosomes from PASMC culture medium are enriched in miR-143-3p, and to a lesser extent, 
the miR-143-5p passenger strand. Therefore, exosomes containing miR-143 and secreted by PAH-
PASMCs might enhance the development of lesions associated with pulmonary hypertension and could 
be of clinical importance. Hence, cell:cell communication between compartments might be critical in 
the pathogenesis of PAH. We observed a reduction in microvessel density in the miR-143-/- hypoxic 
lungs compared to WT, suggesting that miR-143 transport in exosomes could enhance microvessel 
density and lung perfusion. Further experiments will be needed to address this effect in vivo. 
 
 MiRNAs are potential therapeutic targets for several diseases, including PAH. We have shown 
that miR-143, specifically localized to the SMC layers of pulmonary arteries in multiple models of 
disease is also significantly upregulated in human PAH patients.. The Brisket disease samples in 
particular share some common features of the human disease, including right heart failure and the 
development of complex vascular lung lesions. Since expression of miR-143 appears high in both acute 
(murine hypoxia-induced) and chronic (rat sugen/hypoxia and post-mortem human lung and brisket 
disease samples) samples, it suggests that miR-143 expression is elevated and sustained during the 
pathogenesis of PAH, particularly evident in distal small vessels (Figure 6 and Supplementary Figure 
S12). Also, miR-143 manipulation in vitro affected cell migration but not proliferation in both PASMCs 
and PAECs. Next, the chronic hypoxia PH mouse model demonstrated that genetic ablation of miR-
143 prevents the development of PH. To further explore the therapeutic role of miR-143-3p, we 
performed pharmological manipulation of miR-143 in WT mice treated with antimiR. Genetic ablation 
and pharmacological inhibition of miR-143 exert a protective role in the development of PH. We 
previously reported that antimiR-143 did not signficantly reverse indices of PAH17, however, there was 
a trend to lower RVSP. We clearly report here that both a prevention and reversal study show efficacy 
of the antimiR approach. The two results are not inconsistent with each other, due to the consistency in 
the direction of response and the current study having a greater power to declare genuine differences 
between groups as reaching statistical significance given its greater sample size. Ultimately, Caruso et 
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al17 found insufficient evidence to conclude an involvement for miR-143 in development of PAH in 
experimental mice, but the larger sample sizes used in the current study have given us greater statistical 
power and allowed us to find statistically significant evidence as to the function and importance of miR-
143. 
 In conclusion, we have, for the first time, performed detailed experimental characterisation of 
the promoter sequence controlling transcription of the miR-143/145 cluster, unravelling the most 
significant signalling pathways involved. Many of these signalling pathways have previously been 
implicated in the development of PAH, in which the expression of miR-143 is shown to be increased. 
Moreover, this is the first study to show that miRNAs are involved in the crosstalk between PASMCs 
and PAECs in PAH, suggesting that miR-143 may act as a crucial paracrine signalling mediator during 
remodeling of the pulmonary vasculature. Thus our study illustrates a novel role for miR-143-3p as 
therapeutic target in PAH.  
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FIGURE LEGENDS 
 
Figure 1. Analysis of the miR143/145 promoter. (A) Scheme of a 1.5 kb region of the proximal 
promoter. Homology percentage among species is indicated (with arrows). Transcription factor binding 
sites are shown as arrow heads above/below the line if located in the plus/minus strand respectively. 
(B-E)  Estradiol (E2) at 10 nM for 24 hours induced the expression of pri-miR-143/145 (B), mature 
miR-143/145 but not their passenger strands miR143*(miR-143-5p)/145*(miR-145-3p) in PASMC 
(C), and transcriptional activity of the full length promoter p1.5-luc and proximal promoter p0.5-luc in 
HeLa cells (D), dependent on sites located at (-801) and (-14) (E). (F-I) LXR/RXR pathway was 
induced by 9cRA and 22R (5 μM each) for 24 hours in PASMC. The expression levels of pri-miR-
143/145 (F) and mature miR-143/145 and miR-143*/145* (G) were detected by qPCR. Transcriptional 
activity of the promoter was assayed in HeLa cells (H-I). (J-M) Exposure to hypoxia (1% O2 for 24 
hours) increased the expression of pri-miR-143/145 (J), and miR-143/145 and miR-143* in PASMC 
(K). Transcriptional activity was dependent on the hypoxia response element (HRE) located at (-113) 
(M). *p < 0.05, **p < 0.01 and ***p<0.005. 
 
Figure 2. Analysis of the TGF-β pathway in PASMC. (A-B) Pri-miR-143/145 and all four mature 
forms miR143/145 and miR143*/145* were upregulated by 10 ng/ml TGF-β1 for 24 hours, but no 
effect was detected after BMP4 treatment. (C) Transcriptional activation of the miR-143/145 promoter 
was induced by TGF-β1 only in the full length p1.5-luc reporter. (D) Site-directed mutagenesis 
demonstrated the relevance of the Smad binding site at (-592). (E-F) Decoy assay for the Smad3 binding 
site using phosphorothioate oligodeoxynucleotides (PTO-ODN). Only the wild type decoy and not 
those bearing Smad3 SNPs (rs12517403 and rs116423755) inhibits the TGF-β1-induced pri-miR-
143/145 (E) and mature miR-143/145 (F) expression. *p < 0.05, **p < 0.01 and ***p<0.005. 
 
Figure 3. Manipulation of miR-143/145 cluster affects PASMC migration. Expression levels of pri-
miR-143 and pri-miR-145 (A), mature miR-143-3p and miR-145-5p (B) and their respective passenger 
strands miR-143* (miR-143-5p) and miR-145* (miR-145-3p) (C) during scratch closure of PASMC by 
qPCR. (D) Representative micrographs and quantification of a wound healing assay after miR-143 
overexpression by pre-miR-143 transfection, in comparison with vehicle and negative control (NC). 
MiR-143 Expression relative to control by qPCR is shown (E). (F,G) Representative micrographs of a 
wound healing assay after miR-143 knock-down by specific antimiRNA, compared with vehicle or 
negative control (NC). MiR-143 xpression relative to control by qPCR is shown (G). (H-J) Wound 
healing assay with PASMC nucleofected with a GFP reporter in which expression is driven by the miR-
143/145 promoter mainly in cells migrating from the border of the scratch. All experiments were 
repeated at least 3 independent times. *p < 0.05, **p < 0.01 and ***p<0.005. 
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Figure 4. Extracellular miR-143 from PASMCs is transferred to PAEs and induces their 
migration (A) Diagram of the transwell used for the in vitro co-culture system. (B) PASMCs were 
transfected with Cy3-pre-miRNA in the upper chamber. Cy3-labeled, miRNA-enriched exosomes are 
then released and transferred to PAEC in the lower chamber after 24 hours (n=3). (C) Co-culture system 
applied with PASMCs (insert) and PAECs (bottom) for 48 hours to assess the endogenously transfer of 
miR-143 from PASMCs to PAECs, Q-PCR showed the miR-143 expression level in PAECs after co-
culture compared with control (n=6). (D) PASMCs were transfected with pre-miR-143 or negative 
control (NC), co-cultured with PAECs for 24 or 48 hours, and expression of miR-143 was measured in 
PASMCs and PAECs by qPCR (n=3). (E) Representative micrographs and relative migration distance 
of PAEC migration during scratch closure in co-culture with pre-miR-143-transfected PASMC. (F) Q-
PCR showed the expression level of miR-143 in PAECs (n=3). (G) Representative micrographs and 
relative migration distance of PAEC migration during scratch closure with conditioned medium from 
transfected PASMCs. (H) Q-PCR show the expression level of miR-143 in PAECs. (n = 3) *p < 0.05, 
**p < 0.01 and ***p < 0.005. 
 
Figure 5. Released functional extracellular miR-143 in exosomes (A) Taqman qPCR Ct value 
showed miR-143 expression in PASMC and PASMC-derived exosomes. (B) The exosome pellet was 
re-suspended in PBS and visualized on the NanoSight instrument. The analysis shows the size of 
isolated exosomes is between 30-130nm. (C) Western Blot of PASMC-derived exosomes for CD63, 
CD9 and GAPDH. (D-E) Q-PCR analysis of miR-143 expression in PASMCs and PASMC-derived 
exosomes after the cells were transfected with negative control or pre-miR143 (10nM, 50nM and 
100nM). RNU48 and cel-miR-39 were used as internal loading controls for cells and exosomes 
respectively (n=3). (F) Representative micrographs and relative migration distance of PAECs during 
scratch closure, after treatment with isolated exosomes derived from PASMCs transfected with pre-
miR-143, vehicle or negative control (NC). (G) Q-PCR showing the expression level of miR-143 in 
exosomes (n=3). (H) Representative micrographs and relative migration distance of PAECs during 
scratch closure after direct transfection with pre-miR143. (I) Q-PCR showing the expression level of 
miR-143 in PAECs. (n=3) (J) Matrigel angiogenesis assay in PAECs transfected with pre-miR-143 or 
loaded with miR-143 enriched exosomes. Images ×10 magnification, scale bar represents 250μm (n=3). 
(K) Quantification of total tube lengths in PAECS treated with exosomes from pre-miR-143 transfected 
PASMCs (L) Quantification of total tube lengths in PAECS transfected with pre-miR-143. *p<0.05 and 
**p< 0.01, ***p < 0.005. 
 
Figure 6. MiR-143 expression is upregulated in experimental models of PH. Quantitative PCR 
analyses of miR-143 stem-loop in total lung (A) and right ventricle (B) of normoxic and hypoxic mice 
(n=6) were analyzed for miR-143 expression by qPCR. Results were normalized to U6 values. (C) MiR-
143 stem-loop expression in PASMC from female PAH patients and healthy controls by qPCR (n=7). 
(D) In situ hybridization of hypoxic neonatal calf and Brisket Disease calves show increased expression 
of miR-143 compared with healthy controls. (E) In situ hybridization of human lung of pulmonary 
vessels revealed increased miR-143 localized in the smooth muscle layer of constrictive and complex 
arterial lesions of PAH patients. Scale bar = 100 μm. *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
Figure 7. Direct knockout of miR-143 stem loop and pharmacological inhibition of miR-143-3p 
in mice alleviates the development of PH in vivo. (A) Analysis of SAP, (B) Assessment of systolic 
right ventricular pressure (sRVP, n= 9-12) (C), and right ventricular hypertrophy (RVH, n=12) in WT 
and miR-143 KO mice after 14 days hypoxic exposure. (D) Distal pulmonary artery vessel wall 
thickness and remodelling were analyzed by α-smooth muscle actin (α-SMC) and CD31 staining in 
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miR-143 KO mice compared with their WT littermate controls in both normoxia and hypoxia condition 
(n=4, scale bar=20μm). (E) Prevention model with pharmacological inhibition of miR-143-3p in mice 
exposed to chronic hypoxia and in normoxic controls. (F) Systolic right ventricular pressure (RVP, 
n=10-17) and (G) right ventricular hypertrophy (RVH, n=10-17) and (H) SAP were measured in 
normoxia and hypoxia in vehicle, scramble anti-miRNA and anti-miR-143 mice groups (n=10-17). (I) 
Hypoxia rescue model with pharmacological inhibition of miR-143-3p in mice exposed to chronic 
hypoxia. (J) Systolic right ventricular pressure (RVP, n=7-9) and (K) right ventricular hypertrophy 
(RVH, n=10), (L) SAP (n=5/group) were measured. *p < 0.01, **p < 0.01, ***p < 0.001. 
 
Figure 8. Model of the regulation and actions of the miR-143/145 cluster in PAH. Several signalling 
pathways related to the pathogenesis of PAH regulate miR-143/145 expression by activating the 
promoter region of the miR-143/145 cluster in PASMCs. MiR-143-3p can affect cellular migration and 
apoptosis and acts as a paracrine signalling mediator during vascular remodelling. During the 
development of PAH, PASMCs secrete exosomes enriched with miR-143-3p, which are transported to 
PAEC, inducing migration and angiogenesis.  
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SUPPLEMENTAL MATERIAL 
MiR-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary 
arterial hypertension 
 
Short Title: Regulation and role of miR-143 in PAH 
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McBride, John D McClure, Jenny Grant, Matthew Thomas, Maria Frid, Kurt Stenmark, Kevin 
White, Anita G. Seto, Nicholas W. Morrell, Angela C Bradshaw, Margaret R. MacLean, 
Andrew H. Baker 
 
Detailed Methods 
 
Cloning the MIR143HG proximal promoter and reporter vectors 
The location of the theoretical transcription start site (TSS) and proximal promoter region of the miR-
143/145 hosting gene (MIR143HG) in chromosome 5 was predicted by the miRStart tool 
(http://mirstart.mbc.nctu.edu.tw/)1. Homologous sequences from different species were obtained from 
Ensembl database (http://www.ensembl.org) and analyzed with Clustal Omega at European 
Bioinformatics Institute website (http://www.ebi.ac.uk/Tools/msa/clustalo/). The in silico analysis of 
regulatory cis-elements was further carried out with MatInspector (Genomatix software suite, 
http://www.genomatix.de). Then, a primer pair was designed to amplify by PCR a spanning sequence 
of 1556 bp from a human genomic DNA sample: Fw(-1354): 5’-acgcgttgggggtctgaggaactgt; and 
Rv(+202): 5’-agatctctttcctggggtctggtcc, bearing a MluI and BglII targets in the 5’-end, respectively 
(underlined). In parallel, a minimal construction of 506 bp was also generated using an alternative 
MluI-targeted forward primer Fw(-304): 5’-acgcgttgcctccctctctcccct. Then, both PCR products were 
TA-cloned into pCR2.1-TOPO (Invitrogen, Paisley, UK), double digested with MluI/BglII and finally 
cloned into pGL3 basic vector (Promega, Madison, WI, USA) to generate p1.5-Luc and p0.5-Luc 
vectors, respectively. 
In addition, these pGL3 reporter vectors were cleaved by KpnI and BglII. Fragments were purified 
and oriented cloned into the promoterless pLenti-GFP reporter plasmid using its KpnI and BamHI 
sites, as BglII and BamHI produce compatible ends. Final constructions were confirmed by 
sequencing. Thus, these plasmids and the corresponding empty vector were transferred into PASMC 
by nucleofection (Amaxa, Köln, Germany), where the reporter expression of GFP is driven by that 
promoter sequence cloned upstream. No lentivirus is generated in this assay as these reporter vectors 
are used without the corresponding partner plasmids. 
Cell culture and reagents 
Primary culture of female proximal pulmonary artery smooth muscle cells (PASMCs) and pulmonary 
arterial endothelial cells (PAECs) were purchased from Lonza and grown in Clonetics SmGM-s 
BulletKit medium and EBM-2 Endothelial Growth Basal Medium, respectively (Lonza, Walkersville, 
MD, USA). Distal female PASMC from PAH patients were obtained from the Prof. Nicholas W. 
Morrell’s lab (Addenbrooke’s Hospital, University of Cambridge) and maintained in SmGM-s 
medium. Cells were used in early passages and maintained in exponential growth. For hypoxic 
exposure cells were placed into a hypoxic chamber (1% O2, 5% CO2, balance N2) for 24 hours. 
Human epithelial HeLa cells were grown in Eagle's Minimum Essential Medium (Gibco, Paisley, UK) 
plus 10% FBS supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, and 100 U/mL 
penicillin/streptomycin. 
For cell migration assays, ~500µm-wide wounds were systematically created by scratching with a 
sterile pipette tip throughout confluent PASMC monolayers until only 20% of the cells remained 
adherent to the culture dish. Plates were washed, fresh medium was added, and cells were cultured at 
37°C for the indicated times. 
The Smad signalling pathway was assessed by recombinant human TGF-β1 and BMP4 (R&D) and 
the ALK5-specific inhibitor SB525334 (Tocris Bioscience, Bristol, UK). For LXR/RXR activation 
studies, cells were incubated with 22R-Hydroxycholesterol (22R), or 9-cis-retinoic acid (9cRA) 
(Sigma-Aldrich, St. Louis, MO, USA). Estradiol (E2, 17β-estradiol) was used to stimulate the 
estrogen receptor pathway. 
RNA extraction, reverse transcription and TaqMan qPCR Analysis 
Total RNA from PASMCs was obtained using the miRNeasy kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. cDNA for miRNA analysis was synthesized from total 
RNA using specific stem-loop reverse transcription primers according to the TaqMan MiRNA Assay 
protocol (Applied Biosystems, Foster City, CA, USA). Retrotranscription was carried out for 30 
minutes at 16°C, 30 minutes at 42°C, 5 minutes at 85°C and then held at 4°C. Total cDNA for pri-
miRNA and mRNA transcripts analysis was generated from total RNA using the TaqMan® Reverse 
Transcription Reagents (Applied Biosystems) using random hexamers. Reaction was performed for 
10 minutes at 25°C, 30 minutes at 48°C, 5 minutes at 95°C. 
For quantitative PCR (qPCR), 10µl reactions were incubated in a 384-well optical plate at 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Data were normalized 
to RNU48 values for miRNAs and to B2M for pri-miRNAs expression using the 2-ΔΔCt method. 
Results were expressed as fold change relative to the relevant control. The qPCRs were run in 
triplicate and results are presented as the mean ± standard error of samples. 
Luciferase reporter activity and site-directed mutagenesis 
HeLa cells were seeded in 24-well plates and then transfected with the corresponding reporter plasmid 
and pCMV/β-Gal vector with Lipofectamione 2000 (Invitrogen) according to the manufacturer’s 
instructions. After 24 hours, cells were treated or not with the indicated treatment and incubated for an 
additional 24 hours in four replicates at least. Then, cells were washed, lysed and luciferase activity 
was measured with the Luciferase Assay System (Promega) in a plate reader luminometer. Data are 
presented as relative luciferase units (RLU) refereed to β-Galactosidase activity using the Tropix 
Galacton-Plus kit (Applied Biosystems), as an internal control. 
Full length promoter in pGL3 (p1.5-luc) was used as the template for site-directed mutagenesis using 
the GENEART® Site-Directed Mutagenesis System (Invitrogen), following the manufacturer's 
protocol. All the primers used to specifically destroy the response elements introduced also a unique 
restriction enzyme site for a quick confirmation of the reaction. Their sequences are the following: 
Smad3(-592)-S: 5’-GGGAGTAGCTTCCCACGCGTTGGGCTCTCCTTCCC  
Smad3(-592)-AS: 5’-GGGAAGGAGAGCCCAACGCGTGGGAAGCTACTCCC 
LR(-1129)-S: 5’-CCTTGATTTGTGTTTTCTGAATTCTCTTCACAGACAC  
LR(-1129)-AS: 5’-GTGTCTGTGAAGAGAATTCAGAAAACACAAATCAAGG 
LR(-673)-S: 5’-CCCCTGCCCTGTGGTACCCCTGCCAGGTGGCTGGG  
LR(-673)-AS: 5’-CCCAGCCACCTGGCAGGGGTACCACAGGGCAGGGG 
LR(-4)-S: 5’-GGTAAAAGGCAGAGTGGCAGCTGTGGCCAGGGAGCC  
LR(-4)-AS: 5’-GGCTCCCTGGCCACAGCTGCCACTCTGCCTTTTACC 
LR(+98)-S: 5’-GGCACCAGAGGCTGCAGCTAATTAGTTGAGAAGC  
LR(+98)-AS: 5’-GCTTCTCAACTAATTAGCTGCAGCCTCTGGTGCC 
ER(-801)-S: 5’-GAATCTGTAGGATCCCAAGGTGGGCTAGCAAAAGGAG  
ER(-801)-AS: 5’-CTCCTTTTGCTAGCCCACCTTGGGATCCTACAGATTC 
ER(-14)-S: 5’-CATATAAGGTAAAAGCTCGAGTGGCCTCTGTGG  
ER(-14)-AS: 5’-CCACAGAGGCCACTCGAGCTTTTACCTTATATG 
HRE(-1157)-S: 5’-GCCGAGGCCTGGTTCATATGATCCCTTGATTTGTG  
HRE(-1157)-AS: 5’-CACAAATCAAGGGATCATATGAACCAGGCCTCGGC 
HRE(-113)-S: 5’-GGTCAAGGCAAGGTAGTCATATGGGGGGTGCCTGGG  
HRE(-113)-AS: 5’-CCCAGGCACCCCCCATATGACTACCTTGCCTTGACC 
Mutations are in red and the corresponding restriction enzyme target is underlined. All these resulting 
mutant reporters were confirmed by sequencing. 
Smad3 decoy assays 
For transcription factor decoy assays, phosphorothioate oligodeoxynucleotides (PTO-ODN) were 
synthesized and HPLC purified (Eurofins MWG Operon, Ebersberg, Germany). The sense and 
antisense PTO-ODN 3’-ends were protected from nucleases by a phosphorothioate backbone (PTO). 
Moreover, sense ODN was 5’-FAM-labeled for visualisation after transfection. Thus, the sequence for 
the sense (S) and anti-sense (AS) probes was: 
Mock-S: 5'-FAMGGCCTCGTTTGCATGATGATgG 
Mock-AS: 5’-CCATCATCATGCAAACGAGGcC 
WT-S: 5’-FAMCTTCCCACGGTCTGGGCTCTcC 
WT-AS: 5’-GGAGAGCCCAGACCGTGGGAaG 
rs12517403-S: 5’-FAMCTTCCCACGGTCCGGGCTCTcC 
rs12517403-AS: 5’-GGAGAGCCCGGACCGTGGGAaG 
rs116423755-S: 5’-FAMCTTCCCACGGTCTAGGCTCTcC 
rs116423755-AS: 5’-GGAGAGCCTAGACCGTGGGAaG 
Lower case letters indicate where the PTO bond is, Smad3 binding site is underlined and SNPs are in 
red. For probe hybridisation, sense and antisense ODN were mixed at 50 µM each, incubated at 90°C 
for 2 minutes and cooled at room temperature. Then, 100 pmol of double strand probes were 
transfected with Lipofectamine 2000 (Invitrogen) in subconfluent PASMC in 6-wells plates. 
Transfection efficiency was monitored by an epifluorescence microscope. 
Ethical information 
All animal procedures conform to the United Kingdom Animal Procedures Act (1986) and with the 
“Guide for the Care and Use of Laboratory Animals” published by the US National Institutes of 
Health (NIH publication No. 85-23, revised 1996). Animal approval was granted by the University 
Committee Board. Experimental procedures using human PASMCs conform to the principles outlined 
in the Declaration of Helsinki. 
Chronic Hypoxia Mouse model  
MiR-143−/− mice have previously been described 2. Homozygous miR-143−/− female mice or age-
matched wild-type controls (strain C57BL6J/129SVEV, 8 weeks of age) were exposed to chronic 
hypoxia for 14 days or maintained in normoxic conditions and assessed at 10 weeks of age. For the 
reverse study, mice were exposed to chronic hypoxia for 21 days. The development of chronic 
hypoxic PH in mice was achieved with hypobaric hypoxia as previously described 3. 
Hemodynamic Measurements  
For all the experiments, right ventricular systolic pressure (RVSP) was measured in mice under 
isoflurane (1.5% O2) anaesthesia via a needle advance into the right ventricle (RV) trans-
diaphragmatically. Systemic arterial pressure (SAP) was recorded via a cannula placed in the carotid 
artery as previously described 3. Right ventricular hypertrophy (RVH) was determined as ratio of the 
ventricular wall weight to the left ventricle plus septum (LV + S) weight.  
Chronic Hypoxia calf model 
The neonatal calf model of severe hypoxia-induced pulmonary hypertension has been described 
previously 4, and includes the development of pulmonary artery (PA) pressure equal to, or exceeding, 
systemic pressure, accompanied by remarkable PA remodelling with medial and adventitial 
thickening, as well as perivascular inflammation 5, 6. Briefly, one-day-old male Holstein calves were 
exposed to hypobaric hypoxia (PB=445 mmHg) for 2 weeks, while age-matched controls were kept at 
ambient Denver altitude (PB=640 mmHg). Standard veterinary care was used following Institutional 
guidelines, and procedures were approved by Colorado State University IACUC and performed at 
Department of Physiology, School of Veterinary Medicine, Colorado State University (Fort Collins, 
CO). Animals were euthanized by overdose of sodium pentobarbital (160 mg/kg body weight). 
In addition to neonatal calves, older (yearling) animals with naturally-occurring pulmonary 
hypertension were used 7. These animals were of mixed British-based Aberdeen Angus and Hereford 
breeds, they were born at a high altitude (2,438 m) cattle ranch in Southwest Colorado, and pastured 
at 2,438–3,505 m altitude for several months until their incidental death. Post-mortem, lung lesions 
consistent with PH and right-heart failure in the absence of bronchopneumonia were validated.   
Western Blotting 
Protein expression analysis was derived by Western blot analysis as previously described8. Briefly, 
protein was extracted from lung tissues by homogenization and protein quantified using BCA Protein 
Assay Reagent (Thermo Scientific). SDS-PAGE gels (NuPAGE® Novex® 10% Bis-Tris Midi 
Protein Gels) were calibrated with rainbow marker protein standards (Amersham). Anti-PCNA 
(ab18197, 1:1000), anti-FAK (phosphor Y397, ab81298 1:1000), anti- FAK (ab40794 1:1000), anti-
stat3 (phopho Y705, ab76315 1:10,000) and anti-stat3 (ab68153 1:1000) were used as primary 
antibodies (AbCam).  Primary antibodies purchased from Cell Signalling were anti-α-Tubulin (2148), 
AKT (C67E7) and Akt-Ser473 (5473) and these were used at 1:1000.  Two secondary antibodies 
(peroxidase-labeled anti-mouse and anti-rabbit antibodies) were each used at a dilution of 1:2000. For 
protein loading control, the housekeeping protein α-Tubulin was used. Proteins were visualized using 
the ECL Plus Western blotting detection kit (Amersham Biosciences U.K. Ltd).  
Immunohistochemistry  
Mouse tissues were fixed in 4% paraformaldehyde solution at 40°C for 18 hours and embedded in 
paraffin. After deparaffinization with graded concentrations of histoclear and ethanol, slides were 
heated in 10mM pH6.0 Na Citrate for antigen retrieval. Then the sections were incubated with 20% 
normal rabbit or goat serum for 30 minutes to reduce non-specific background staining. The sections 
were then incubated with PCNA (Abcam) or CD31 (1:20 Dianova) in 2% rabbit or goat serum in PBS 
or IgG control and incubated at 4℃ overnight. Sections were then incubated with Extravidin-
Peroxidase LSAB reagent (Sigma E2886) or the appropriate biotinylated secondary antibody (Dako, 
High Wycombe, UK) diluted in 1:200 in PBS. DAB solution (Vector Labs SK-4100) was applied for 
3 or 5 minutes. The nuclei were counterstained with hematoxylin for 1min; followed by dehydration 
of sections.  
For the calves IHC staining was performed as previously described9, with either IgG control 
antibodies (Vector Labs, Burlingame, CA), or smooth muscle myosin heavy chains (SM-MHC)-
specific rabbit polyclonal antibodies (1:2000 dilution), kindly provided by Dr. R.S. Adelstein 
(National Heart, Lung, and Blood Institute, NIH, Bethesda, MD).  For the human lung IHC staining 
was performed as previously described 10, with mouse monoclonal antibody against α-smooth muscle 
actin (Dako, Clone 1A4, High Wycombe, UK) or isotype matched mouse IgG nonimmune control 
(Dako, High Wycombe, UK).  For hematoxylin and eosin staining of RV, sections were incubated 
with hematoxylin solution (Sigma-Aldrich, Poole, UK) for 5 minutes and then rinsed in water, washed 
in 95% alcohol and counterstained in eosin Y solution (Sigma-Aldrich).  For mouse lung 
immunofluorescence, after deparaffinization sections were incubated in 30% goat serum for 30 min, 
then with primary antibodies against CD31 (Dianova, dilution 1:20), α-sma (Sigma, dilution 1:200) 
and IgG-control  in PBS-1%BSA overnight at 4℃. Secondary antibodies (Alexa Fluor®, dilution 
1:500) were incubated for 1 hour at room temperature. Then slides were mounted in ProLong® Gold 
antifade reageant with Dapi (Molecular Pobes).  
In situ hybridization  
For the detection of miR-143 in hypoxia-exposed neonatal calves, brisket disease cattle, mouse RV 
and human PAH patient lung samples, 5µm sections were rehydrated with histoclear and graded 
concentrations of ethanol. Then slides were boiled for 10 minutes in DEPC treated 10mM sodium 
citrate buffer (PH6.0) for antigen retrieval and immersed in 0.2M HCL for 20 minutes. After washing 
three times, 0.3% triton-X was added on the slides for 10 minutes, then incubated with 10µg 
proteinase K at 37℃ for 15 minutes and finally fixed with 4% PFA for 10 minutes. Following 
incubation with hybridization buffer (50% formamide, 4 x SSC, 2.5 x Denhadrt’s solution, 2.5mg/ml 
salmon DNA, 0.6mg/ml yeast tRNA, 0.025% SDS and 0.1% blocking reagent) at 60°C for 1 hour 
slides were incubated with 40nM miR-143 or scramble miRCURY LNATM Detection probe, 5’-DIG 
labeled (Exiqon, Denmark) in the same buffer at 60°C overnight. After stringency washing with 
different concentrations of SSC buffer and blocking (1% blocking reagent in PBS and 10% FCS) anti-
DIG antibody (Roche Applied Science, Indianapolis, IN, USA) was added 1:500 overnight. After 
washing (0.1M Tris PH 9.0) BM purple solution or NBT/BCIP solution (Roche Applied Science, 
Mannheim, Germany) was added to each section respectively and left at room temperature overnight. 
The slides were checked the next day and mounted with Vectamount AQ (Vector Labs).  
Proliferation assay  
Cell proliferation was measured by BrdU incorporation using Proliferation Assay Kit (Millipore BrdU 
Cell Proliferation Assay Kit) according to the manufacturer’s instructions. Briefly, transfected and 
control PASMCs were seeded (1 x 104) in 96 well plates 24 hours and then serum starved for 48 hours 
in 0.2% serum containing medium. Then PDGF was added for 72 h at 20ng/ml. BrdU diluted medium 
was added to each well in 96 well plates after 5 h PDGF stimulation.   
Microarray 
Microarray analysis of PASMC and PAECs transfected with scramble or pre-miR-143. RNA quantity 
and quality were assessed by NanoDrop® Spectrophotometer (Thermo Scientific,  Wilmington, DE, 
USA). RNA integrity was assessed with the Agilent 2100 bioanalyser using the RNA 
6000 Nano Kit (Santa Clara, CA). The Illumina TotalPrep RNA amplification kit (Ambion) was used 
to generate biotinylated, amplified RNA, from 500ng input RNA, for hybridization with the Illumina 
arrays (Applied Biosystems Carlsbad, California). The Illumina humanHumanHT-12 v4.0 Expression 
BeadChips were hybridised following the manufacturer’s protocol, scanned with the Illumina 
BeadArray Reader and read into Illumina GenomeStudio® software (version 1.1.1).  
For microarray data analysis and validation, quantile normalised and background subtracted intensity 
values were exported from GenomeStudio® software for data processing and analysis in R 
(http://www.R-project.org) in which limma statistical analysis was carried out11, including pairwise 
comparisons between the 3 groups.  The microarray data and experimental design was submitted 
online to the ArrayExpress database (www.ebi.ac.uk/arrayexpress) following MIAME guidelines.  
The accessions E-MTAB-3566 and E-MTAB-3567 were allocated to the PAEC and PASMC arrays 
respectively.  To gain further biological insights into the gene expression profiling experiments, 
pathway analysis was performed using Ingenuity Pathway Analysis software (Ingenuity Systems, 
www.ingenuity.com). To account for potentially subtle changes in levels of gene expression caused 
by the action of miRNAs and to ensure these changes were included in the pathway analysis we used 
a fold change threshold of ± 1.25. 
Isolation of adult mouse cardiomyocytes and heart fibroblasts 
Cardiomyocytes were isolated as previously described using the cannulation of the aorta method12.  
To isolate heart fibroblasts hearts were minced in ADS buffer and serially digested (4 repeats of 25 
minutes) in 310u/mg collagenase type 2 (Worthington) and pancreatin (Sigma). After every digestion, 
the enzyme mix was removed from the heart pieces into a falcon tube with FCS, spun down and 
resuspended in FCS to build up a stock of cells.  
Wound Healing Assay 
PASMCs or PAECs with different treatments were incubated at 37℃ in 5% CO2 until a complete 
monolayer was formed. After serum starvation for 24 hours, straight scratches for each well were 
made with a 200ul pipette tip. The wells were then rinsed with PBS, which was replaced with regular 
media. Pictures were captured at 0h and 10h or 12h time points, and then the migration distances were 
analysed by Image J.  
Transfection of PASMC cells with Cy3-labeled pre-miR-143 precursor 
Pre-miR miRNA precursor (has-miR-143-3p, Ambion) was labeled with Label IT siRNA Tracker 
Cy3 Kit, according to the manufacture’s instructions (Mirus, Madison, WI, USA). PASMC cells ( 1.5 
x 105) were transfected with 100nm of Cy3 labeled pre-miR miRNA precursor using siPort 
(Invitrogen, ABI). The day after transfection, cells were washed with PBS, and the medium was 
switched to fresh exosome-free medium. After incubation for 36 hours, the culture medium was 
collected and used for exosome preparation.  
Co-culture experiments 
Well inserts for 6 well plates with a 0.4 µm pore-sized filter were purchased from Greiner and used 
following the manufacturer’s instructions. PASMCs (1.5 x 105) in the well inserts with pre-miR143 
(100nM) transfection by siPORT (Invitrogen) according to the manufacturer’s instructions 
simultaneously and cultured in complete SMC medium for 24h. PAECs (2 x 105) were seeded into the 
6-well plate with EBM medium. Before starting the co-culture experiments both PASMCs and 
PAECs were washed with PBS then the insert with transfected PASMC was put into the 6-well plate 
with PAECs. All co-culture experiments were done in complete EBM.  
Isolation of exosomes from cell media 
Cell media from PASMCs with different treatments were centrifuged at 2000g for 30 min to remove 
cell debris. The supernatant containing the cell free cell media was transferred to a clean tube and held 
on ice until use. Then each sample was combined with total exosome isolation reagent (Invitrogen) 
and mixed well by vortexing until a homogenous solution was formed. The samples were incubated at 
4°C overnight and then centrifuged at 4 °C at 10000 g for 1 h. The supernatant was aspirated and 
discarded, and the exosome pellet was resuspended in PBS buffer, then stored at 4°C for short term 
(1-7 d) and -20 °C for long term until use.  NanosightTM and protein analysis by western blot for 
CD63 (H-193: sc-15363) and CD9 (H-110: sc-9148) were carried out to test the purity of the exosome 
isolation.  
DNA Damage 
 PASMC were treated with TNF-α (100ng/ml), IL-6 (100nm) and PDGF (30ng/ml) for 48 hours as 
previous study13. Immunofluorescence for Υ-H2AX was performed as previously reported14 using a 
monoclonal antibody directed against Υ-H2AX (ab11174, Abcam).  
Apoptosis Assay  
Pre-miR143/Scramble transfected PASMCs and PAECs and PAECS treated with miR-143 enriched 
exosomes derived from PASMCs were seeded in 96-well plates. After 24 hours of transfection, 
PASMCs were treated with H2O2 (50µm) for 12 hours and PAECs were treated with Cycloheximide 
(CHX, 25ng/ml) and TNF-α (4ng/ml) for 7 hours. The standard protocol for cells cultured in a 96-well 
plate of Caspase-Glo® 3/7 Assay (Promega, G8091) was followed according to the manufacturer’s 
protocol.  
In Vitro Angiogenesis  
Evaluation of tube formation by PAECs was performed using an In Vitro Angiogensis Assay Kit 
(ECM625; Mliiipore, Billerica, CA). PAECs transfected with pre-miR143/Scramble or treated with 
miR-143 enriched exosomes derived from PASMCs were cultured on ECMatrix, a solid gel 
consisting of basement membrane proteins, growth factors, and proteolytic enzymes. Briefly, 
ECMatrix gel solution was thawed, mixed with diluent buffer, and 50µl was transferred to each well 
of a pre-cooled 96-well tissue culture plate. This was incubated at 37°C for 1.5 hours to allow the 
matrix solution to solidify. Treated PAECs were harvested, resuspended in media, seeded 1 x 104 
cell/well onto the surface of the polymerized ECMatrixTM and incubated at 37°C for 6-12 hours. The 
extent of proangiogenesis was quantified by measuring the total tube length in 5 randomly selected 
fields (x 100 magnification) for each well. Experiments were conducted in triplicate.  
Statistical analysis 
All statistical calculations were carried out using GraphPad Prism. Student’s t-tests were used when 
comparing two conditions and a one-way ANOVA with Bonferroni and Tukey correction was used 
for multiple comparisons. Probability values of less than 0.05 were considered significant.  
 
 
 
A 
5-aza-2-dC (PASMC) 
0 
1 
2 
3 
4 
*** 
*** 
*** 
*** 
ns 
ns 
pri-miR-143 pri-miR-145 
R
Q
 (t
o 
B
2M
) 
B 
5-aza-2-dC (PAEC) 
0.0 
0.5 
1.0 
1.5 
2.0 
R
Q
 (t
o 
B
2M
) 
C 
5-aza-2-dC (HUVEC) 
0.0 
0.5 
1.0 
1.5 
R
Q
 (t
o 
B
2M
) 
pri-miR-143 pri-miR-145 
pri-miR-143 pri-miR-145 
Online Figure I 
   
Supplemental Figures and Figure Legends 
Online Figure I. Analysis of the effect of methylation on pri-miR-143 
expression. Human pulmonary artery smooth muscle cells (PASMC) (A), 
pulmonary artery endothelial cells (PAEC) (B) and umbilical vein endothelial cells 
(HUVEC) (C) were treated with the demethylating agent 5-aza-2’-deoxycytidine 
(5aza) for 24 hours and with or without TGF-β for an additional 24 hours. 
Expression levels of pri-miR-143 and pri-miR-145 were detected by qPCR. 
***p<0.001 and ns, not significant.  ***p<0.005. 
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Online Figure II. The effect of TGFβ on miR-143 and miR-145 expression. 
PASMC were treated with or without 10 ng/ml TGF-β in 0.2% FCS medium for 24 
hours. In addition, cells were pre-treated with the TGF-β/ALK5-specific inhibitor 
SB525334 at 1 nM for 30 minutes as indicated. Pri-miR-143 and pri-miR-145 
precursors (A), mature lead strands miR-143-3p and miR-145-5p (B), and 
corresponding passenger strands miR-143-5p (miR-143*) and miR-145-3p 
(miR-145*) (C) were detected by qPCR. *** p<0.001. 
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Online Figure III. Expression of pri-miR-143 and pri-miR-145 in response to a 
dose response to Smad3 decoy probes. Increasing amounts of WT decoy probe 
were transfected into PASMC. Total amount of decoy probe was corrected with a 
scramble sequence (mock). After 6 hours post-tranfection, cells were treated with 
or without 10 ng/ml TGF-β for additional 24 hours. Pri-miR-143 and pri-miR-145 
were detected by qPCR. Expression of α1 chain of type I collagen (COL1A1) was 
used as a TGF-β responsive control gene. ***p<0.001. 
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Online Figure IV. Comparative analysis of PASMC migration in control and 
PAH donor cells. Cells were grown in monolayer and the expression levels of 
miR-143 and miR-145 precursors and mature forms were detected by TaqMan 
qPCR at the indicated time after the scratch in control PASMC (84MP) (A). In 
parallel, PASMC from either idiopatic or hereditable PAH patients, 37MP (IPAH) (B) 
and 73MP (HPAH) (C) respectively, were also assayed. *p<0.05. **p<0.01. 
***p<0.001. 
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Online Figure V. Cell migration in response to transcriptional regulators of 
miR-143. PASMC monolayers were scratched and then incubated for 0, 3, 8, 16, 
21 and 24 hours with the indicated treatment (A), Control with vehicle; (B), 10 ng/
ml TGF-β; (C), 10 nM Estradiol; (D), 5 µM 9cRA; (E), 5 µM 22R-
Hydroxycholesterol; (F), 5 µM 9cRA and 5 µM 22R-Hydroxycholesterol). Left 
panels show expression levels of pri-miR-143 and pri-miR-145 detected by qPCR, 
whereas right panels show cell migration during scratch closure at the same time 
points. Data are represented as mean ± SD. 
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Online Figure VI. Proliferation and apoptosis of PASMCs in response to 
modulation of miR-143 levels. (A), Human PASMCs were transfected with pre-
miR143 or negative control and pulsed with BrdU 6 hours after 20 ng/ml PDGF 
stimulation for 72 hours. BrdU incorporation did not change in miR-143 groups 
compared with NC (n=6). (B), Expression of the proliferation marker PCNA was 
quantified in PASMCs 72 hours after transfection with pre-miR143 or negative 
control. Immunoblotting revealed no differences upon miR-143 transfection (n=3). 
(C), PASMC apoptosis with pre-miR-143 and anti-miR-143 transfection were 
measured by caspase 3/7 activity (n=8). (D), Q-PCR assess the miR-143 in 
PASMC with TNF-α (100ng/ml), IL-6 (100nm) and PDGF (30ng/ml) treatment for 
48 hours. (E), Υ-H2AX nuclear staining shown the PASMC DNA damage induced 
by TNF-α, IL-6 and PDGF. (n=3) Scale bar=20µm *p<0.05, **p<0.01, ***p<0.001. 
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Online Figure VII. Pathway analysis by microarray. Selected significant 
functional annotation relating to increased ‘migration of cancer cells’ (p < 1.43x10-4) 
using Ingenuity Pathway Analysis. Orange represents an increase in migration of 
cancer cells, green fill represents decrease and red an increase in gene expression 
levels in mir-143 transfected cells compared to controls. 
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Online	   Figure	   VIII. Western blot analysis for potential mediators of the PAH 
phenotype.	   (A), FAK phosphorylation was assessed in wild type (WT) and 
miR-143 knock out (miR-143 KO) lungs from mice exposed to normoxic or hypoxic 
conditions. Results were normalized by densitometry to total FAK (n=3). (B), FAK 
phosphorylation was assessed in PASMCs transfected with scramble or 
premiR-143. Data were analysed using a two-way ANOVA n=3. (C), Stat 3 
(phospho Y705) phosphorylation was assessed in both control PASMCs and 
PASMCs 24hrs after multiple scratches (migrating) by western blot. Total stat 3 was 
used as an endogenous control. Results were normalized by densitometry to total 
stat3 (n=6). (D), The expression level of miR-143 was assessed by q-PCR in 
control and migrating PASMCs. 
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Online Figure IX. Proliferation and apoptosis of PAECs in response to 
modulation of miR-143 levels, and antimiR-143 transfection inhibited the 
miR-143-enriched exosome mediated PAEC migration. (A), Human PASMCs 
were transfected with pre-miR143 or negative control and pulsed with BrdU 6 hours 
after 20 ng/ml PDGF stimulation for 72 hours. BrdU incorporation did not change in 
miR-143 groups compared with NC (n=6). (B), Expression of the proliferation 
marker PCNA was quantified in PASMCs 72 hours after transfection with pre-
miR143 or negative control. Immunoblotting revealed no differences upon miR-143 
transfection (n=3). (C), PAEC apoptosis with pre-miR-143 transfection or (D) 
miR-143 enriched exosomes derived from PASMCs were measured by Caspase 
3/7 activity (n=8). (E), PAECs exposure to exosome derived from PASMC 
transfected with Cy3 labeled pre-miR-143 and assess the red fluorescence by 
fluorescent microscope. Control exosomes as negative control. Scale bar= 20µm 
(n=3). (F), miR-143 expression in PAEC with exosomes exposure, antimiR-143 
transfection alone and miR-143-enriched exosomes derived from PASMC together 
with antimiR-143 transfection. (G), Relative migration distance in PAEC showed 
that the miR-143 enriched exosomes derived from PASMCs exposure induced 
migration could be inhibited by antimiR-143 transfection. (n=3). *p < 0.05, 
***p<0.001. 
Online Figure X 
  
Online Figure X. Pathway analysis by microarray. Selected significant functional 
annotation relating to decrease in ‘cell death and survival’ (p < 1.56 x 10-3) using 
Ingenuity Pathway Analysis. Blue represents an decrease in ‘cell death of B 
lymphocytes’, green fill represents decrease and red an increase in gene 
expression levels in mir-143 transfected cells compared to controls. 
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Online Figure XI 
  
A 
Online Figure XI. In situ hybridization showing miR-143 localisation in RV from 
mice exposed to normoxic or hypoxic conditions and miR-143 expression in 
Fibroblast and Cardiomyocytes. (A), Paraffin sections were rehydrated and 
incubated with an anti–miR-143 or scramble probe as negative control. Hematoxylin 
and eosin (H&E) stains were used to identify cardiomyocytes. Images ×40 
magnification, bar represents 50µm (n=5). (B), The expression level of miR-143 and 
miR-143* was assessed by q-PCR in cardiac fibroblasts and cardiomyocytes.  
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Online Figure XII. In situ hybridization analysis of miR-143 expression in 
paraffin sections obtained from Brisket disease and control calves and 
miR-143 expression in different stages of rat SUGEN model. (A), A scramble 
probe was used as negative control. MiR-143 expression in distal pulmonary 
arteries was significantly upregulated in Brisket disease compared with controls. 
Images all x40 magnification, scale bars = 100µm. (B), miR-143 detected by qRT-
PCR in lung from male rats exposed to normoxic or hypoxic conditions for 2 wks 
coupled with subcutaneous administration of 20 mg/kg SU5416 on day 0, followed 
by varying lengths of time in normoxic conditions. Total study time indicated on x-
axis. Arbitrary value of 1 assigned to 14 wk normoxia + vehicle. Data represented 
as fold change ± SEM and analysed by a one-way ANOVA followed by Tukey’s 
post hoc test, n = 5 animals per group. *p<0.05, **p<0.01, ***p<0.001 vs 14 wk 
normoxia + vehicle, ##p<0.01 vs time matched normoxia + SU5416. 
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Online Figure XIII. Assessment of AKT. (A), AKT phosphorylation (phospho 
Ser473) was analysed by Western blot in WT and miR-143KO RV from mice. (B), 
AKT phosphorylation was normalized by densitometry to total AKT. Data were 
analysed using a t-test (n=6). For all data an arbitrary value of 1 was assigned to 
the control group. 
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Online Figure XIV. Histological sections of the right ventricles and total lung 
from wild type and miR-143 knock out (miR-143KO) mice, stained for RV 
capilarisation. CD31 staining (A) and IgG control (B) were performed and 
microvessel density was quantified (C). Images ×40 magnification, scale bar 
represents 50µm (n=5). (D),microvessel density was quantified in the total lung 
sections of miR-143-/- and WT hypoxia mice by CD31 and α-SMA staining (n=4). 
*p < 0.05 .  
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Online Figure XV. Validation of the antimiR-143 study and analysis of PCNA. 
(A), Q-PCR confirmed the miR-143 knockdown in total lung and pulmonary arteries 
(PA) with antimiR-143 injection in normoxia in vivo (n=8). (B) and (C), Q-PCR 
confirmed the miR-143 knockdown in total lung, pulmonary arteries (PA) and right 
ventricles (RV) of prevention and reversal PH model with antimiR-143 injection 
under chronic hypoxia conditions in vivo  (n=8). (D), Expression of the proliferation 
marker PCNA was quantified in the total lung protein of WT and miR-143 KO 
chronic hypoxia mice (n=4). (E), Immunohistochemical analysis showed there was 
no difference of PCNA expression on the pulmonary arteries of WT and miR-143 
KO chronic hypoxia mice (n=4). *p < 0.05, **p < 0.01 and ***p<0.005. 
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Online Figure XVI. Vascular remodeling of the miR-143 pharmacological 
inhibition PH mice models. (A), Distal pulmonary artery vessel wall thickness 
and remodeling were analyzed by α-smooth muscle actin (α-SMC) and CD31 
staining in both prevention and reversal PH model by anti-miR-143 injection 
compared with control groups (n=5, scale bar=20µm). *p < 0.05, **p < 0.01 
Supplemental Tables 
Supplementary Table I. Disease and function annotation relating to migration in the smooth 
muscle cell gene expression dataset. 
Categories 
Diseases or 
Functions 
Annotation p-Value 
Gene 
Count Molecules 
Cellular 
Movement 
 
migration of 
brain cells 5.53E-05 9 APP,BTG2,CDK5,FN1,FUT10,GNA13,LAMA1,PTEN,RERE 
 
migration of 
breast cancer 
cell lines 2.96E-03 12 
ANKS1A,CCL5,CTGF,CTNNB1,CTSL,DDR2,FLNA,FN1,GIT1,MLLT4,
SNAI2,TGM2 
 
migration of 
cancer cells 1.43E-04 13 
ADAM10,AHCY,CCL5,CSF2RA,CTBP2,CTGF,CTNNB1,F3,FN1,IL11,
LAMA5,PTEN,SNAI2 
 
 
 
 
 
 
 
migration of 
cells 3.64E-04 68 
ADAM10,ADORA1,AHCY,ANGPTL4,ANKS1A,APP,ARHGDIA,ASAP2
,BBS1,BTG2,CCL5,CCR5,CD58,CD63,CDK5,CSF2RA,CTBP1,CTBP
2,CTGF,CTNNA1,CTNNB1,CTSL,DDR2,DIAPH1,DOCK3,F3,FCAR,F
LNA,FN1,FUT10,FUT8,GIT1,GNA13,GNG12,HDAC3,HDC,HLA-
G,HRH1,IL11,JAK1,LAMA1,LAMA5,LDLR,LPA,MATN2,MLLT4,MYOC
D,PKD1,PKM,PLEC,PRRX1,PTEN,PTPRU,RERE,RHOG,SCARB1,S
EMA3E,SLC3A2,SLC9A1,SNAI2,SPRY4,TGM2,TP53INP1,TPT1,TRP
V1,WHSC1,YWHAE,YY1AP1 
 
migration of 
central nervous 
system cells 2.37E-05 10 APP,BTG2,CDK5,CTGF,FN1,FUT10,GNA13,LAMA1,PTEN,RERE 
 
migration of 
chondrosarcom
a cells 1.03E-02 2 CCL5,IL11 
 
migration of 
embryonic cells 3.08E-03 7 CCL5,CDK5,FN1,IL11,LAMA1,LAMA5,SLC3A2 
 
migration of 
endothelial cells 9.72E-03 14 
ADAM10,ANGPTL4,CCL5,CD63,CTGF,F3,FLNA,FN1,HRH1,PKM,PT
EN,SCARB1,SEMA3E,SPRY4 
 
migration of 
extravillous 
trophoblast cells 3.00E-03 2 CCL5,IL11 
 
migration of 
fibroblast cells 3.48E-03 8 CTNNB1,FN1,GNG12,PKD1,PTEN,RHOG,TGM2,TP53INP1 
 
migration of 
glioma cells 9.43E-03 3 CSF2RA,CTGF,F3 
 
migration of 
hepatic stellate 
cells 6.56E-03 3 CCL5,CCR5,CTGF 
 
migration of 
kidney cell lines 1.57E-03 7 ANKS1A,APP,CCL5,CCR5,FN1,PKD1,RHOG 
 
migration of 
leukemia cells 5.33E-04 7 APP,CCL5,CCR5,FLNA,FN1,GNA13,TGM2 
 
migration of 
melanoma cells 8.41E-03 3 ADAM10,FN1,SNAI2 
 
migration of 
monocytes 6.45E-03 6 APP,CCL5,CTGF,FN1,JAK1,LDLR 
 
migration of 
mononuclear 
leukocytes 6.50E-03 16 
ADAM10,APP,CCL5,CCR5,CD58,CTGF,DIAPH1,FN1,GNA13,HDC,H
LA-G,JAK1,LDLR,PLEC,PTEN,TGM2 
 2.12E-03 3 APP,BTG2,FUT10 
migration of 
neural 
precursor cells 
 
migration of 
neuroglia 
 
9.97E-03 
 
5 
 
APP,CTGF,FN1,MATN2,PTEN 
 
migration of 
neurons 2.06E-03 13 
ADAM10,BBS1,CDK5,CTNNB1,DIAPH1,FLNA,FN1,GNA13,LAMA1,M
ATN2,PTEN,RERE,YWHAE 
 
migration of 
pancreatic 
cancer cell lines 2.92E-03 4 CDK5,FN1,PRRX1,TP53INP1 
 
migration of 
pericytes 7.70E-04 4 CCL5,CCR5,CTGF,FN1 
 
migration of 
phagocytes 1.16E-02 12 
APP,CCL5,CCR5,CD58,CTGF,DDR2,FLNA,FN1,JAK1,LDLR,PTEN,T
RPV1 
 
migration of 
prostate cells 4.45E-03 2 FN1,WHSC1 
 
migration of 
Purkinje cells 4.24E-05 4 CDK5,GNA13,PTEN,RERE 
	  
	  
	  
	  
Supplementary Table II. Gene expression data from the ‘migration of cancer cell’ functional 
annotation relating to migration in the smooth muscle cell gene expression dataset. 
	  
Symbol Illumina p-value Log Ratio 
Entrez Gene ID 
for Human 
ADAM10 ILMN_2148360 0.00749 0.32705 102 
AHCY ILMN_1657862 0.00741 -0.33416 191 
CCL5 ILMN_2098126 0.00023 0.45211 6352 
CSF2RA ILMN_1661196 0.00239 0.44034 1438 
CTBP2 ILMN_3250209 0.00809 0.39629 1488 
CTGF ILMN_2115125 0.00012 -0.61260 1490 
CTNNB1 ILMN_1746396 0.00256 -0.36541 1499 
F3 ILMN_2129572 0.00201 0.37686 2152 
FN1 ILMN_1778237 0.00041 -0.45445 2335 
IL11 ILMN_1788107 0.00526 0.33755 3589 
LAMA5 ILMN_1773567 0.04814 -0.34166 3911 
PTEN ILMN_1880406 0.00718 -0.32989 5728 
SNAI2 ILMN_1655740 0.03198 -0.34327 6591 
	  
	  
	  
	  
	  
	  
	  
	  
	  	  
Supplementary Table III. Gene expression data from the ‘cell death and survival’ functional 
annotation relating to survival in the endothelial cell gene expression dataset. 
Categories 
Diseases or 
Functions 
Annotation p-Value Gene Count Molecules 
 
Cell Death and 
Survival 
 
apoptosis of 
follicular B 
lymphocytes 1.25E-03 2 BCL2A1,CD80 
 
 
cell death of B 
lymphocytes 1.56E-03 5 BCL11A,BCL2A1,CD80,MS4A1,VAV3 
 
 
apoptosis of pro-B 
lymphocytes 4.58E-03 2 BCL11A,VAV3 
 
 
apoptosis of B-2 
lymphocytes 6.00E-03 1 BCL2A1 
 
 
apoptosis of B 
lymphocytes 7.40E-03 4 BCL11A,BCL2A1,CD80,VAV3 
 
 
apoptosis of 
germinal center B 
lymphocytes 1.79E-02 1 CD80 
 
 
loss of long-lived 
plasma cell 1.79E-02 1 CD80 
 
 
cell death of 
lymphoblastoid cell 
lines 2.12E-02 3 RAP1GDS1,TGIF2LX,VAV3 
 
 
apoptosis of 
leukocyte cell lines 2.71E-02 4 BCL2A1,IKZF3,MS4A1,PMAIP1 
 
 
apoptosis of 
prostate cancer cell 
lines 2.85E-02 4 HOXC6,IGFBP1,ILK,PMAIP1 
 
 
apoptosis of B-
lymphocyte derived 
cell lines 4.02E-02 3 BCL2A1,MS4A1,PMAIP1 
 
 
cell viability of germ 
cell tumor cell lines 4.13E-02 1 PMAIP1 
 
 
apoptosis of 
fibrosarcoma cell 
lines 4.31E-02 2 BCL2A1,PMAIP1 
 
 
anoikis of breast cell 
lines 4.70E-02 1 ILK 
	  
 
 
 
 
 
 
 
 
 
  
Supplementary Table IV. Gene expression data from the ‘cell death and survival’ functional 
annotation relating to survival in the endothelial cell gene expression dataset. 
Symbol Illumina p-value Log Ratio 
Entrez Gene ID 
for Human 
BCL11A ILMN_1752899 0.00215 0.36538 53335 
BCL2A1 ILMN_1769229 0.00205 0.35285 597 
CD80 ILMN_1716736 0.00333 -0.32993 941 
MS4A1 ILMN_1776939 0.00339 -0.39392 931 
VAV3 ILMN_2290068 0.00137 0.35903 10451 
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